Recent research on the application of biologics in the treatment of multisystem inflammatory syndrome in children after SARS-CoV-2 infection.
10.7499/j.issn.1008-8830.2111005
- Author:
Han-Yu CUI
1
;
Chang-Ping HU
1
Author Information
1. Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410078, China.
- Publication Type:Journal Article
- Keywords:
Biologics;
Child;
Multisystem inflammatory syndrome;
Severe acute respiratory syndrome coronavirus 2
- MeSH:
Biological Products;
COVID-19/complications*;
Child;
Humans;
SARS-CoV-2;
Systemic Inflammatory Response Syndrome
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(2):216-222
- CountryChina
- Language:English
-
Abstract:
Multisystem inflammatory syndrome in children (MIS-C) is a type of hyperinflammatory symptoms similar to Kawasaki disease after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is commonly observed in children aged 8-10 years. Primary therapeutic medications for MIS-C are intravenous immunoglobulins and glucocorticoids. It has been reported that biologics, such as IL-1 receptor antagonist anakinra, IL-6 receptor antagonist tocilizumab, and TNF-α receptor antagonist infliximab, can be used as an option for critically ill patients. This article elaborates on the mechanism of action of the above biologics and discusses the efficacy and safety biologics in the treatment of MIS-C after SARS-CoV-2 infection, in order to provide methods for the treatment of MIS-C with severe symptoms.
